How it all began
Alcyomics technologies represent the fruits of over 30 years’ research activity on transplantation and graft versus host disease in the research laboratories of Professor Anne Dickinson at Newcastle University.
Skimune® was originally developed for identifying responses of donor cells against patient skin tissue i.e. graft versus host disease (GvHD) following haematopoietic stem cell transplantation. This work has been extensively published in peer-reviewed journals (see References and Patents). The technology has been further modified by Alcyomics, not just for the testing of drugs for allo-immune responses (i.e. transplant rejection) but also for predicting contact sensitivity and allergic reactions with development of novel IP (see References and Patents).
Skimune® has been used as a predictive assay for GvHD in Newcastle as part of a clinical protocol for treatment of haematological disorders and has been published to have a >80% correlation with clinical outcome. Since GvHD affects more than one target organ e.g skin, gut and liver, Skimune® is predictive of systemic disease.